Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million

NEXT STORY
Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
PREV STORY
Immunochemistry Analyzers (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology Annual Meeting

– Responses to Selective TRK Inhibitor Observed Across Tumor Types Harboring TRK Fusions – ...

author_avatar
NASDAQ Market News

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Technology

WALTHAM, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the ...

author_avatar
NASDAQ Market News

Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital

author_avatar
NASDAQ Market News